-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Great news! Shijiazhuang No.4 Pharmaceutical’s Metronidazole Sodium Chloride Injection has achieved industry-leading status in its reviewed packaging format.
Category:
Time：2022-09-28
On September 28, the upright polypropylene infusion bag packaging for metronidazole sodium chloride injection (250 ml: 1.25 g and 100 ml: 0.5 g), developed by Shijiazhuang Fourth Pharmaceutical, once again received national drug registration approval, securing another “entry ticket” for participation in the national centralized drug procurement.
Autumn is the season of bountiful harvests, and Shijiazhuang Fourth Pharmaceutical has been receiving one good news after another regarding its innovative R&D achievements. Entering September, following the approval of two specifications of metronidazole sodium chloride injection packaged in polypropylene infusion bottles—250ml: 1.25g and 100ml: 0.5g—as well as methycobalamin injection (1ml: 0.5mg) and valsartan amlodipine tablets (Type I), all of which were deemed to have passed the evaluation of generic drug quality and efficacy consistency, on September 28, Shijiazhuang Fourth Pharmaceutical’s upright polypropylene infusion bag-packaged metronidazole sodium chloride injection (250ml: 1.25g and 100ml: 0.5g) once again received national drug registration approval, securing yet another “entry ticket” for participation in the national centralized drug procurement.
It is understood that Metronidazole Sodium Chloride Injection is primarily used in clinical practice for the treatment of anaerobic bacterial infections. Previously, the multilayer co-extruded film infusion bags and polypropylene infusion bottles—two packaging formats for Metronidazole Sodium Chloride Injection (250 ml: 1.25 g and 100 ml: 0.5 g)—developed by Shijiazhuang Fourth Pharmaceutical, respectively passed the National Generic Drug Quality and Efficacy Consistency Evaluation in February 2021 and September 2022. With the recent approval of the upright polypropylene infusion bag packaging for Metronidazole Sodium Chloride Injection (250 ml: 1.25 g and 100 ml: 0.5 g), Shijiazhuang Fourth Pharmaceutical has now achieved a leading position among domestic pharmaceutical companies in terms of the number of packaging formats for this product that have successfully passed the evaluation.
Over the past two years, Shijiazhuang No.4 Pharmaceutical has leveraged a series of business-friendly policies supported by Shijiazhuang—policies designed to help the biopharmaceutical industry achieve breakthroughs—to continuously increase its R&D investment. The company has collaboratively advanced research and innovation in generic drugs, innovative drugs, active pharmaceutical ingredients, biopharmaceuticals, and pharmaceutical packaging materials, overcoming a number of critical core technologies that had previously been “bottlenecked.” As a result, an increasing number of innovative achievements have emerged, and the company’s R&D efforts are now entering a period of concentrated “harvest.” Since the beginning of this year, the company has obtained 32 product approvals, including 22 formulation approvals. To date, a total of 29 drug varieties comprising 38 specifications have either passed or been deemed equivalent to passing the national evaluation of quality and therapeutic equivalence for generic drugs. With industry-leading R&D efficiency and approval rates, these continuous innovations are strengthening and empowering the company, helping it move toward the mid-to-high end of the value chain.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license